NCT01614041View on ClinicalTrials.gov

Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder

PHASE4CompletedINTERVENTIONAL
Enrollment

274

Participants

Timeline

Start Date

January 10, 2012

Primary Completion Date

September 11, 2018

Study Completion Date

July 31, 2019

Conditions
Generalized Anxiety Disorder
Interventions
DRUG

Usual dose treatment of Tandospirone

Usual dose treatment of Tandospirone, oral, 30 mg/day

DRUG

Comparative high dose of tandospirone treatment

Comparative high dose of tandospirone treatment, oral, 60 mg/day

Trial Locations (1)

200065

Shanghai Tongji Hospital, Shanghai

All Listed Sponsors
lead

Sumitomo Pharma (Suzhou) Co., Ltd.

INDUSTRY

NCT01614041 - Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder | Biotech Hunter | Biotech Hunter